Clinical utility of genomic signatures in early-stage breast cancer - INAHTA Brief

Evaluate the clinical utility of four genomic signatures (GS)^[1], currently and temporarily funded on a conditional basis as part of a specific funding program for research and innovation (known in France as RIHN). The aim of the evaluation is to assess funding eligibility for the traditional reimbursement schemes offered by the National Health Insurance Fund.